Acute Kidney Injury (AKI) - Pipeline Insight, 2020 -

DUBLIN--()--The "Acute Kidney Injury (AKI) - Pipeline Insight, 2020" drug pipelines has been added to's offering.

This report outlays comprehensive insights of present clinical development scenario and growth prospects across the Acute Kidney Injury (AKI) market. A detailed picture of the Acute Kidney Injury (AKI) pipeline landscape is provided, which includes the disease overview and Acute Kidney Injury (AKI) treatment guidelines. The assessment part of the report embraces in-depth Acute Kidney Injury (AKI) commercial assessment and clinical assessment of the Acute Kidney Injury (AKI) pipeline products from the pre-clinical developmental phase to the marketed phase.

In the report, a detailed description of the drug is proffered including mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Acute Kidney Injury (AKI) collaborations, licensing, mergers and acquisition, funding, designations, and other product-related details.

Report Highlights

  • A better understanding of disease pathogenesis contributing to the development of novel therapeutics for Acute Kidney Injury (AKI) .
  • In the coming years, the Acute Kidney Injury (AKI) market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
  • The companies and academics that are working to assess challenges and seek opportunities that could influence Acute Kidney Injury (AKI) R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition.
  • A detailed portfolio of major pharma players who are involved in fueling the Acute Kidney Injury (AKI) treatment market. Several potential therapies for Acute Kidney Injury (AKI) are under investigation. With the expected launch of these emerging therapies, it is expected that there will be a significant impact on the Acute Kidney Injury (AKI) market size in the coming years.

Key Questions Answered

  • What are the current options for Acute Kidney Injury (AKI) treatment?
  • How many companies are developing therapies for the treatment of Acute Kidney Injury (AKI)?
  • What are the principal therapies developed by these companies in the industry?
  • How many therapies are developed by each company for the treatment of Acute Kidney Injury (AKI)?
  • How many Acute Kidney Injury (AKI) emerging therapies are in early-stage, mid-stage, and late stage of development for the treatment of Acute Kidney Injury (AKI)?
  • Out of total pipeline products, how many therapies are given as a monotherapy and in combination with other therapies?
  • What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, and major licensing activities that will impact Acute Kidney Injury (AKI) market?
  • Which are the dormant and discontinued products and the reasons for the same?
  • What is the unmet need for current therapies for the treatment of Acute Kidney Injury (AKI)?
  • What are the recent novel therapies, targets, mechanisms of action and technologies developed to overcome the limitation of existing Acute Kidney Injury (AKI) therapies?

Key Topics Covered:

1. Report Introduction

2. Acute Kidney Injury (AKI)

2.1. Overview

2.2. History

2.3. Acute Kidney Injury (AKI) Symptoms

2.4. Causes


2.6. Acute Kidney Injury (AKI) Diagnosis

2.6.1. Diagnostic Guidelines

3. Acute Kidney Injury (AKI) Current Treatment Patterns

3.1. Acute Kidney Injury (AKI) Treatment Guidelines

4. Acute Kidney Injury (AKI) - Analytical Perspective

5. Therapeutic Assessment

5.1. Clinical Assessment of Pipeline Drugs

5.1.1. Assessment by Phase of Development

5.1.2. Assessment by Product Type (Mono / Combination)

5.1.3. Assessment by Route of Administration

5.1.4. Assessment by Molecule Type

5.1.5. Assessment by MOA

5.1.6. Assessment by Target

6. Acute Kidney Injury (AKI) Late Stage Products (Phase-III)

7. Acute Kidney Injury (AKI) Mid Stage Products (Phase-II)

8. Early Stage Products (Phase-I)

9. Pre-clinical Products and Discovery Stage Products

10. Inactive Products

11. Dormant Products

12. Acute Kidney Injury (AKI) Discontinued Products

13. Acute Kidney Injury (AKI) Product Profiles

13.1. Drug Name: Company

13.1.1. Product Description Product Overview Mechanism of action

13.1.2. Research and Development Clinical Studies

13.1.3. Product Development Activities Collaboration Agreements Acquisition Patent Detail

13.1.4. Tabulated Product Summary General Description Table

14. Acute Kidney Injury (AKI) Key Companies

15. Acute Kidney Injury (AKI) Key Products

16. Dormant and Discontinued Products

16.1. Dormant Products

16.1.1. Reasons for being dormant

16.2. Discontinued Products

16.2.1. Reasons for the discontinuation

17. Acute Kidney Injury (AKI) Unmet Needs

18. Acute Kidney Injury (AKI) Future Perspectives

19. Acute Kidney Injury (AKI) Analyst Review

20. Appendix

21. Report Methodology

Companies Mentioned

  • Sentien Biotechnologies, Inc.
  • Angion Biomedica Corp.
  • Astellas Pharma Inc
  • Atox Bio Ltd

For more information about this drug pipelines report visit

Laura Wood, Senior Press Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

Laura Wood, Senior Press Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900